As­traZeneca un­veils pos­i­tive Phase 3 da­ta to move Imfinzi in­to ear­li­er stages of lung can­cer

As­traZeneca is mov­ing its block­buster can­cer drug Imfinzi in­to ear­li­er stages of small cell lung can­cer, a dis­ease that has not seen in­no­va­tion in stan­dard of care for four decades.

Tout­ing topline da­ta from its Phase 3 ADRI­AT­IC tri­al on Fri­day, As­traZeneca said Imfinzi demon­strat­ed a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in the co-pri­ma­ry end­points of over­all sur­vival and pro­gres­sion-free sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER